Levodopa and the progression of Parkinson's disease Parkinson Study Group New England Journal of Medicine 351 (24), 2498-2508, 2004 | 2301 | 2004 |
Unified Huntington's disease rating scale: reliability and consistency K Kieburtz, JB Penney, P Como, N Ranen, I Shoulson, A Feigin, ... Movement disorders 11 (2), 136-142, 1996 | 2010 | 1996 |
Brain Blood Flow Measured with Intravenous H215O.: II. Implementation and Validation ME Raichle, WRW Martin, P Herscovitch, MA Mintun, J Markham Journal of Nuclear Medicine 24 (9), 790-798, 1983 | 1336 | 1983 |
Diffusion tensor imaging of white matter tract evolution over the lifespan C Lebel, M Gee, R Camicioli, M Wieler, W Martin, C Beaulieu Neuroimage 60 (1), 340-352, 2012 | 1170 | 2012 |
Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL‐PET study AL Whone, RL Watts, AJ Stoessl, M Davis, S Reske, C Nahmias, AE Lang, ... Annals of neurology 54 (1), 93-101, 2003 | 1049 | 2003 |
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group DE Hobson, AE Lang, WRW Martin, A Razmy, J Rivest, J Fleming Jama 287 (4), 455-463, 2002 | 733 | 2002 |
Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. MA Mintun, ME Raichle, WR Martin, P Herscovitch Journal of nuclear medicine: official publication, Society of Nuclear …, 1984 | 726 | 1984 |
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study Parkinson Study Group Archives of Neurology 59 (12), 1937-1943, 2002 | 695 | 2002 |
Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology JM Miyasaki, W Martin, O Suchowersky, WJ Weiner, AE Lang Neurology 58 (1), 11-17, 2002 | 584 | 2002 |
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Parkinson Study Group Archives of Neurology 61 (4), 561-566, 2004 | 578 | 2004 |
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease Huntington Study Group Neurology 57 (3), 397-404, 2001 | 504 | 2001 |
Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study K Duff, JS Paulsen, LJ Beglinger, DR Langbehn, JC Stout, ... Biological psychiatry 62 (12), 1341-1346, 2007 | 466 | 2007 |
Midbrain iron content in early Parkinson disease: a potential biomarker of disease status WRW Martin, M Wieler, M Gee Neurology 70 (16_part_2), 1411-1417, 2008 | 457 | 2008 |
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 427 | 2012 |
Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease DB Calne, JW Langston, WRW Martin, AJ Stoessl, TJ Ruth, MJ Adam, ... Nature 317 (6034), 246-248, 1985 | 425 | 1985 |
Preparing for preventive clinical trials: the Predict-HD study JS Paulsen, M Hayden, JC Stout, DR Langbehn, E Aylward, CA Ross, ... Archives of neurology 63 (6), 883-890, 2006 | 390 | 2006 |
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Ninds Net-Pd Investigators Neurology 66 (5), 664-671, 2006 | 387 | 2006 |
Nigrostriatal function in humans studied with positron emission tomography WRW Martin, MR Palmer, CS Patlak, DB Calne Annals of Neurology: Official Journal of the American Neurological …, 1989 | 348 | 1989 |
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit MF Beal, D Oakes, I Shoulson, C Henchcliffe, WR Galpern, R Haas, ... JAMA neurology 71 (5), 543-552, 2014 | 299 | 2014 |
Longitudinal change in regional brain volumes in prodromal Huntington disease EH Aylward, PC Nopoulos, CA Ross, DR Langbehn, RK Pierson, JA Mills, ... Journal of Neurology, Neurosurgery & Psychiatry 82 (4), 405-410, 2011 | 297 | 2011 |